Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database
Sign Up to like & getrecommendations! Published in 2023 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2022.7476
Abstract: Key Points Question Do the demographics, clinicopathologic characteristics, and prognosis differ between breast cancers with no erb-b2 receptor tyrosine kinase 2 (ERBB2; formerly HER2 or HER2/neu) expression (ERBB2 negative) and those with low-level ERBB2 expression… read more here.
Keywords: low breast; breast cancer; clinicopathologic characteristics; erbb2 low ... See more keywords
Interobserver Variability in HER‐2 Immunostaining Interpretation of Metastatic HER2 Low Breast Cancers in Cytology Specimens
Sign Up to like & getrecommendations! Published in 2024 at "Diagnostic Cytopathology"
DOI: 10.1002/dc.25392
Abstract: Approximately, 55% of breast carcinomas are reported to be HER‐2 low breast carcinomas. Trastuzumab‐Deruxtecan is a new FDA‐approved targeted therapy for HER‐2 low metastatic breast carcinomas, making it essential that all efforts are made to… read more here.
Keywords: variability immunostaining; breast; cytology specimens; low breast ... See more keywords
HER2-low breast cancers: Current insights and future directions.
Sign Up to like & getrecommendations! Published in 2022 at "Seminars in diagnostic pathology"
DOI: 10.1053/j.semdp.2022.07.003
Abstract: In light of the significant clinical benefits of novel HER2-targeting antibody-drug conjugates in advanced HER2-low expressing breast cancers in recent phases I and III clinical trials, particularly trastuzumab-deruxtecan (T-Dxd), the new "HER2-low" category in breast… read more here.
Keywords: low breast; breast; pathology; her2 low ... See more keywords
HER2-Low Breast Cancers.
Sign Up to like & getrecommendations! Published in 2021 at "American journal of clinical pathology"
DOI: 10.1093/ajcp/aqab117
Abstract: OBJECTIVES Recent clinical trials have demonstrated significant clinical benefits from novel therapeutic compounds in breast cancer patient with human epidermal growth factor receptor 2 (HER2) immunohistochemical (IHC) score of 1+ or 2+ and negative in… read more here.
Keywords: low breast; her2 low; breast; breast cancer ... See more keywords
Molecular and clinical traits of HER2-low breast cancer patients and their relationship with neoadjuvant treatment effectiveness
Sign Up to like & getrecommendations! Published in 2024 at "European Journal of Cancer Prevention"
DOI: 10.1097/cej.0000000000000924
Abstract: Background We aimed to investigate the clinical and molecular characteristics of different degrees of human epidermal growth factor receptor 2 (HER2) protein expression in HER2-negative breast cancer and the related factors affecting the efficacy of… read more here.
Keywords: cancer; her2 low; breast cancer; low breast ... See more keywords
Abstract B47: Silver nanoparticles exhibit subtype specific cytotoxic and therapeutic effects in claudin low breast cancer in vitro and in vivo
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.epso16-b47
Abstract: Triple negative breast cancers (TNBC) are characterized by loss of expression of hormone receptors and decreased expression of the human epidermal growth factor receptor 2 (HER2). TNBC patients do not benefit from current targeted breast… read more here.
Keywords: low breast; breast; clbc; breast cancer ... See more keywords
Abstract P5-10-16: HER2-Low Breast Cancer: The Impact of Online Education on Oncologists’ Knowledge and Confidence in Understanding the Latest Advances and Implications for Practice
Sign Up to like & getrecommendations! Published in 2025 at "Clinical Cancer Research"
DOI: 10.1158/1557-3265.sabcs24-p5-10-16
Abstract: Background: HER2-low has been receiving wide-spread interest and is now a therapeutically relevant biomarker in breast cancer. The objective of this study was to assess the effect of an online continuing medical education (CME) activity… read more here.
Keywords: cancer; her2 low; breast cancer; low breast ... See more keywords
Effect of neratinib on HER2 mRNA stability via hsa-miR-23a-5p and efficacy of CDK4/6 inhibitors in HER2-low breast cancer.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e12550
Abstract: e12550 Background: Traditional HER2-negative breast cancer sometimes includes HER2-low components, and CDK4/6 inhibitors are the first- and second-line treatments for advanced HER2-low breast cancer. Nonetheless, little is understood about how the stability of HER2 mRNA… read more here.
Keywords: breast cancer; her2 low; low breast;
Mutational landscape of HER-2 low breast cancer.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e13040
Abstract: e13040 Background: HER2-low breast cancer is defined as HER2 IHC score of 1+ or 2+/ISH- tumors. Anti-Her-2 therapies such as trastuzumab deruxtecan improve progression-free survival (PFS) and overall survival (OS) in patients with HER-2 low… read more here.
Keywords: breast cancer; her2 low; breast; low breast ... See more keywords
Pathological complete response and prognosis after neoadjuvant chemotherapy in patients with HER2-low breast cancer.
Sign Up to like & getrecommendations! Published in 2023 at "Annals of diagnostic pathology"
DOI: 10.2139/ssrn.4333242
Abstract: BACKGROUND The development of novel human epidermal growth factor receptor 2 (HER2) antibody drug conjugates brings encouraging opportunities for the treatment of HER2-low breast cancer. In this study, we investigated the clinical factors and prognosis… read more here.
Keywords: low breast; her2 zero; her2; breast cancer ... See more keywords
Targeted Approaches to HER2-Low Breast Cancer: Current Practice and Future Directions
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14153774
Abstract: Simple Summary HER2-low breast cancer (BC) accounts for more than half of breast cancer patients. Anti-HER2 therapy has been ineffective in HER2-low BC, for which palliative chemotherapy is the main treatment modality. The definitive efficacy… read more here.
Keywords: low breast; her2; breast cancer; her2 low ... See more keywords